Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06428019
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-05-20
Brief Title:
A Study to Evaluate the Risk of Tumor Lysis Syndrome TLS in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia CLL
Sponsor:
AbbVie
Organization:
AbbVie
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-22
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-10-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10-21
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-20
First Submit QC Date:
May 20 2024
Study First Post Date:
2024-05-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-21
Last Update Post Date:
2024-06-28
Last Update Post Date Type:
ACTUAL